ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Cancer cells exploit phenotypical plasticity and epigenetic reprogramming to evade targeted treatments.
• Mechanisms of lineage plasticity and therapy resistance acquisition in cancer remain poorly understood.

Purpose of the Study:

• To identify mechanisms of lineage plasticity and therapy resistance in prostate cancer.
• To investigate the role of zinc finger protein 397 (ZNF397) in androgen receptor (AR)-driven prostate cancer.
• To explore therapeutic strategies against AR-targeted therapy resistance.

Main Methods:

• Identified ZNF397 as a coactivator of the androgen receptor (AR).
• Investigated the role of ZNF397 deficiency in promoting lineage plasticity.
• Assessed the efficacy of a ten-eleven translocation 2 (TET2) inhibitor in overcoming therapy resistance.

Main Results:

• ZNF397 deficiency promotes a transition to a TET2-driven lineage plastic state, conferring resistance to AR-targeted therapies.
• A TET2 inhibitor effectively eliminated therapy resistance in ZNF397-deficient prostate tumors.
• Uncovered a novel epigenetic mechanism driving prostate cancer lineage plasticity and therapy resistance.

Conclusions:

• ZNF397 plays a bifurcated role in regulating prostate cancer lineage plasticity and therapy response.
• A TET2-driven epigenetic mechanism is crucial for tumor adaptation and resistance.
• Targeting TET2 offers a promising strategy to overcome AR-targeted therapy resistance in prostate cancer.